Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes

Karanges, Emily A; Ting, Natasha; Parker, Lisa; Fabbri, Alice; Bero, Lisa

doi:10.31128/ajgp-08-19-5041

Cited by 15 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…After data collection, a descriptive analysis of payment data was conducted overall and by the demographic characteristics, including average and median monetary values per physician and the proportion of physicians receiving payments. Then, as previous studies repeatedly found, 16,25–27 there was a significant difference in the payments between general physicians and leading physicians, namely, key opinion leaders, we performed the multivariable modified log‐linked Poisson regression model for relative likelihood to receive personal payments by physician characteristics and the multivariable negative regression model for relative monetary values by physician characteristics. This study defined the leading PHOs as those who were professors at universities or university hospitals as of March 2022, positioned in the JSPHO board member in March 2022, and authors of clinical practice guidelines issued by the JSPHO between 2015 and 2020.…”

Section: Methodsmentioning

confidence: 99%

“…30 Furthermore, 89.3% of executive board members in the Japan Pediatric Society received payments with a median of $3853 (IQR: 2734-11 552). 30 Considering international reports, 24.4% of leaders of PMSs received payments in Australia, 27 and 72% of board members of PMS received payments in the United States. 26 endorsed by PMSs.…”

Section: Comparing Our Findings With Other Studies Outsidementioning

confidence: 99%

See 2 more Smart Citations

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019

Kamamoto

Murayama

Kusumi

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Comparing Our Findings With Other Studies Outsidementioning

confidence: 99%

See 1 more Smart Citation

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019

Kamamoto

Murayama

Kusumi

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…At PHC level, there is often a lack of experience and expertise, gaps in knowledge, fear of hypoglycaemia, missing guidelines and even fear of prescribing insulin [35,36]. Additional challenges to insulin prescribing include the fact that some health professionals no longer know how to use human insulin as they have received their training in contexts where only analogue insulin is used [37] and the possible impact that the pharmaceutical industry might have on prescribing decisions of doctors [38,39].…”

Section: Human Insulin Analogue Insulinmentioning

confidence: 99%

A global perspective on the issue of access to insulin

et al. 2021

View full text Add to dashboard Cite

The discovery of insulin in 1921 changed the prognosis for people with type 1 diabetes. A century later, availability and affordability of insulin remain a challenge in many parts of the globe. Using the WHO’s framework on understanding the life cycle of medicines, this review details the global and national challenges that affect patients’ abilities to access and afford insulin. Current research and development in diabetes has seen some innovations, but none of these have truly been game-changing. Currently, three multinational companies control over 95% of global insulin supply. The inclusion of insulin on the WHO’s Prequalification Programme is an opportunity to facilitate entry of new companies into the market. Many governments lack policies on the selection, procurement, supply, pricing and reimbursement of insulin. Moreover, mark-ups in the supply chain also affect the final price to the consumer. Whilst expenses related to diabetes are mostly covered by insurance in high-income countries, many patients from low- and middle-income countries have to pay out of their own pockets. The organisation of diabetes management within the healthcare system also affects patient access to insulin. The challenges affecting access to insulin are complex and require a wide range of solutions. Given that 2021 marks the centenary of the discovery of insulin, there is need for global advocacy to ensure that the benefits of insulin and innovations in diabetes care reach all individuals living with diabetes. Graphical abstract

show abstract

“…3 Researchers in Australia have used the information about payments to doctors that is posted on the website of Medicines Australia (MA) to examine interactions between medical professionals and pharmaceutical companies. [4][5][6] However, payments to medical societies are not included in the reports from companies to MA and therefore sponsorship of these organisations has not been studied. This study investigates sponsorship of Australian and New Zealand societies by healthcare companies.…”

Section: Introductionmentioning

confidence: 99%

Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study

Lexchin

2022

JRSM Open

View full text Add to dashboard Cite

Summary Objectives To examine sponsorship of Australian and New Zealand medical societies by healthcare companies and whether societies have policies to deal with conflicts of interest. Design Cross-sectional study conducted in March 2022. Setting Australia and New Zealand Participants Medical societies in both countries. Main outcome measures The percent of medical societies that list sponsorship from healthcare companies on either their home webpages or the webpages of their annual meetings and/or that issue prospectuses to potential sponsors. The percent of societies with sponsorship that also have policies about their interactions with their sponsors. Whether societies feature their sponsors’ logos on their webpages and have hyperlinks to sponsors’ webpages and what percent of societies' annual revenue comes from sponsorships. Results Ninety-two medical societies were identified. Sixty-two had healthcare company sponsorship and 10 of the societies with sponsorship had policies to deal with interactions with their sponsors. Fifty-four societies displayed the logos of their sponsors on their home webpages and/or the webpages of their annual meetings. Only 6 societies provided enough information to calculate what percent of their revenue comes from sponsorships. For 5 of the 6 the percent was well below 50%. Conclusions The acceptance of sponsorships from healthcare companies by Australian and New Zealand societies is common and few societies have policies to deal with these relationships. In general, societies appear to get only a small percent of their annual revenue from sponsorships.

show abstract

Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes

Cited by 15 publications

References 8 publications

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019

A global perspective on the issue of access to insulin

Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study

Contact Info

Product

Resources

About